Ram Aiyar, Ph.D., MBA, is the Chief Executive Officer and President of Korro Bio, and sits on the Board of Directors. Ram brings nearly two decades of diverse experience in biotech and pharma, working across all stages of development from launch to clinical to commercialization. He has a long history of launching and building biotech … Read more
Ali Behbahani, M.D., member of Korro Bio’s Board of Directors, joined New Enterprise Associates (NEA) in 2007 and is currently a general partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a … Read more
Nessan Bermingham, Ph.D. is the co-founder and chairman of the board of directors of Korro Bio. He is also a founder, CEO and President of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups … Read more
Jean-François Formela, co-founder and board member of Korro Bio, is a partner at Atlas Venture and focuses on novel drug discovery approaches and therapeutics. He joined Atlas in 1993 to build the U.S. life sciences franchise. He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA) and Triplet Therapeutics. Jean-François also … Read more
Kate Knobil is a seasoned pharmaceutical executive with over 25 years of experience in global clinical development, medical affairs, and patient safety across large pharma, biotech, and MedTech. Kate has strategically led research and development resulting in regulatory approval and launch of blockbuster medicines. Kate previously served as the Chief Medical Officer at GlaxoSmithKline … Read more
Rachel Meyers is an entrepreneurial scientist currently consulting within the biotech community. Most recently she served as the Founder and Chief Scientific Officer at Faze Medicines, a Third Rock Ventures-spawned biotech company focused on treating diseases of high unmet need through the perturbation of biomolecular condensates. Rachel has more than twenty-five years of drug discovery … Read more
Timothy Pearson serves as the Chief Executive Officer of Carrick Therapeutics, a privately held oncology company. Mr. Pearson served as an Executive Vice President and the Chief Financial Officer of TESARO, Inc., an oncology-focused biopharmaceutical company, from 2014 until its acquisition by GlaxoSmithKline in February 2019. He served as an Executive Vice President, Chief Financial … Read more